Correction to: Unexpected Benefit from Alpelisib and Fulvestrant in a Woman with Highly Pre-treated ER-Positive, HER2-Negative PIK3CA Mutant Metastatic Breast Cancer
- 330 Downloads
1 Correction to: Clinical Drug Investigation (2018) 38(11):1071–1075 https://doi.org/10.1007/s40261-018-0696-3
Conflict of interest, which previously read:
The authors declare that they have no competing interests.
Dr. Arteaga serves on an Advisory Board for Novartis and was a consultant for AstraZeneca from 2015 to 2016. All other authors declare that they have no competing interests.